Article PDF first page preview

First page of Fetoscopic endoluminal tracheal occlusion in congenital diaphragmatic hernia: Unraveling the impact of prematurity and suboptimal fetal lung growth

Introduction Congenital diaphragmatic hernia (CDH) poses significant challenges in both prenatal diagnosis and postnatal management. Fetoscopic endoluminal tracheal occlusion (FETO) aims to enhance survival rates among patients with severe CDH, defined by an observed-to-expected lung-to-head ratio (o/e LHR) of less than 25%. However, issues such as preterm delivery and suboptimal fetal lung growth (SFLG) complicate outcomes. This study examines the effects of these critical risks on FETO results. Methods Data were retrospectively gathered from the multi-institutional CDH Study Group registry on patients with CDH who underwent FETO between 2015 and 2023. Key metrics included CDHSG stage, gestational age (with preterm defined as <37 weeks), o/e-LHR, FETO details, and survival outcomes. The primary outcome was survival, correlated with lung growth and prematurity. Results Among 4,524 CDH patients, 106 (2.3%) received FETO, however, 43 patients had o/e-LHR data. Analyses revealed an overall survival rate of 72.1%, though survival for patients delivered preterm with SFLG decreased to 57.1%, while survival among term patients with any increase in fetal lung growth was 90.0%. In univariate analyses, the balloon inflation duration (p=0.05), the use of extracorporeal life support (p=0.04), and the post-balloon o/e LHR (p=0.04) were associated with survival, while in a multivariable logistic regression, the change in o/e-LHR after FETO (OR=1.07, p=0.05) was the only variable found to be significantly associated with survival. Conclusion Prematurity and SFLG are critical factors linked to decreased survival in FETO, with improved o/e-LHR correlating with better outcomes. Future research should focus on refining patient selection and procedural protocols, with a particular focus on mitigating known complications such as preterm delivery and SFLG, to enhance survival rates.

Journal Section:
Fetal Therapy
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.